Glenmark Therapeutics Inc., USA announced today the launch of its Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative that will compete directly with Bayer’s MiraLAX.
The shares of Glenmark Pharmaceuticals Limited were trading at ₹1,399.35 down by ₹5.05 or 0.36 per cent on the NSE today at 10.15 am.
The new product, containing 17 grams of polyethylene glycol per capful, enters a market with substantial sales potential. According to Nielsen data cited in the announcement, the MiraLAX Powder market achieved annual sales of approximately $555.7 million for the 52-week period ending February 22, 2025.
“We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, addressing the growing demand for a new supplier in this category,” said Marc Kikuchi, President & Business Head, North America for Glenmark.
Glenmark Pharmaceuticals is a global pharmaceutical company with operations in over 80 countries and 11 manufacturing facilities across four continents. The company focuses on respiratory, dermatology, and oncology therapeutics across branded, generic, and OTC segments.
The company ranks among the top 100 biopharmaceutical companies according to Scrip 100 and in the top 50 generics and biosimilar companies according to Generics Bulletin. In 2023, Glenmark received approval from the Science Based Target initiative for its greenhouse gas emission reduction targets.
